The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Lucas Wards - Ascendiant Capital Markets, LLC - Analyst
: Hi, guys. Thanks for the overview. My first question is on G&A expenses. Those have really been coming down pretty dramatically over the last six
quarters, really. I was wondering what your expectations are for G&A run rate in Q4 and into next year?
Question: Lucas Wards - Ascendiant Capital Markets, LLC - Analyst
: Okay, great. Just a follow-up question on the revenue front. In terms of the overall market opportunity, you mentioned, I think last quarter that if
you could convert just 1% of the so-called failed CPAP revenues from the DMEs for instance, that might be enough to get you to breakeven. So
clearly, there's a very large sort of penetration opportunity there. I'm wondering like what would be the catalysts -- catalyst or catalysts to really
convert those sales into the Vivos?
Question: Lucas Wards - Ascendiant Capital Markets, LLC - Analyst
: Okay, great, Kirk. If I could, with just one more question. You had this uptick in the ring lease revenues, up 300% versus last year. To what extent is
that an indicator of future sales in other areas, given that that's sort of a testing program.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 14, 2023 / 10:00PM, VVOS.OQ - Q3 2023 Vivos Therapeutics Inc Earnings Call
Question: Lucas Wards - Ascendiant Capital Markets, LLC - Analyst
: Great, thank you very much.
|
